Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

A user shared their 5-month progress using a topical treatment with finasteride, minoxidil, and retinoic acid, noting some hair growth but also shedding. Another user encouraged them, sharing their own experience of gradual improvement over 12 months and advising patience.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

The post discusses a successful hair loss treatment involving a hair transplant, finasteride, and minoxidil. The user underwent a 2000 graft hair transplant at the hairline in a clinic in Sweden.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The user shared a 4-5 month update on using finasteride, minoxidil, vitamins, oiling, and microneedling for hair loss. They reported improved hair density and confidence but experienced unwanted hair growth, thin hair, itching, and a flaky scalp.

The conversation discusses hair loss treatments, specifically oral Minoxidil, also known as Loniten or Alotendin in Bulgaria. It also mentions considering IndiaMart for purchasing options.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

A user noticed hair loss since age 16 and is now using minoxidil 5% twice daily, scalp massages, and a derma stamp weekly, along with Alpecin Caffeine Shampoo. They report seeing new hair growth and are happy with the progress.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

The user shared progress pictures after a year of treating hair loss with 5% minoxidil, then a combination of minoxidil/finasteride topical, and microneedling at 1.5mm bi-weekly. They plan to switch to oral finasteride and more frequent microneedling at a shallower depth while continuing the current regimen.

A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The user shared 60-day progress using 5% topical minoxidil, 1mg finasteride, and recently started microneedling with a derma stamp. Users commented on the difficulty of seeing changes due to hair length and even thinning.

The conversation discusses hair loss treatments, specifically using 5% minoxidil foam, Vitamin B12, and Vitamin D, with suggestions to add oral finasteride and minoxidil for better results. Concerns about side effects, particularly from finasteride, and the need for a DHT blocker are also highlighted.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

Microneedling and Platelet-Rich Plasma (PRP) are equally effective for treating androgenetic alopecia, with no additional benefits from PRP over microneedling. Both treatments are safe and well-tolerated.

PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.

A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.

The conversation is about finding a place to buy 0.025% topical finasteride in liposomal gel form in Europe. The user previously mixed their own with stemoxydine but stopped due to an oily scalp.

A 27-year-old male has been using 1mg finasteride and 2.5mg oral minoxidil daily for androgenetic alopecia, seeing good results in 3 months but experiencing thinning and density loss. He seeks advice on his Norwood scale level and when density might return.

Taking 1000mg l-arginine alongside 0.5 mg finasteride every other day helped alleviate erectile dysfunction and possibly increased libido. The user recommends trying l-arginine for those experiencing sexual side effects from finasteride.

A user shared a 1.5-year hair loss treatment progress using 1mg Finasteride and 5% Minoxidil, planning to switch to oral Minoxidil and considering adding RU58841. They saw gradual improvement, suspecting Finasteride as the main contributor since they might not respond to topical Minoxidil.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

The user has been using oral finasteride, topical minoxidil, and a dermaroller for hair regrowth, noticing most improvement between months 3 and 4. Other users commented on the positive results and shared their own treatment routines.